Noticias

Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes

mayo 24, 2024

Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.

Efficacy of Mepolizumab in Patients With COPD With or Without Chronic Bronchitis

mayo 20, 2024

The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.

Phenotypes, Etiotypes, and Endotypes of Exacerbations of COPD

mayo 17, 2024

This article examines exacerbations of COPD, emphasizing the need for identifying distinct etioendophenotypes to develop targeted therapies and improve current modest outcomes.

RESPrimaria 1ª Edición: 8 de Mayo de 2024 en formato híbrido

mayo 7, 2024

Más de 900 sanitarios se reunirán de forma presencial y online, este miércoles en Barcelona, para mejorar la prevención y el tratamiento de las
patologías respiratorias.

TRIPLE THERAPY AND CLINICAL CONTROL IN B+ COPD PATIENTS: A PRAGMATIC, PROSPECTIVE, RANDOMIZED TRIAL

mayo 6, 2024

Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control

Coffee Talk: CADSET-explaining the lung function tracker tool

abril 22, 2024

The latest episode of Coffee Talk sees co-chairs of the ERS Clinical Research Collaboration CADSET, Prof. Erik Melén and Prof. Rosa Faner, catch up to discuss the topic of the new lung function tracker tool.

Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD

abril 18, 2024

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous condition. We hypothesized that the unbiased integration of different COPD lung omics using a novel multi-layer approach may unravel mechanisms associated with clinical characteristics.

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

abril 1, 2024

Some patients with COPD suffer frequent exacerbations (FE). We hypothesised that their systemic proteomic profile would be different from that of non-frequent exacerbators (NFE).

Peripheral Immune Cell Profiling Reveals Distinct Immune Hallmarks in Progressive Pulmonary Fibrosis

marzo 29, 2024

This study shows that patients with f-ILDs several immune populations in circulating blood, skewed toward an aged and exhausted immune profile, relate to lung function impairment at diagnosis, and that PPF is associated with an increased cytotoxic immune response.

Pulmonary vascular reactivity in growth restricted fetuses using computational modelling and machine learning analysis of fetal Doppler waveforms

marzo 25, 2024

Pulmonary vascular reactivity in FGR using computational modelling and machine learning analysis of fetal Doppler waveforms

Noticias

Organizing Pneumonia in Hospitalized COVID-19 Patients: Risk Factors and Long-term Outcomes

Efficacy of Mepolizumab in Patients With COPD With or Without Chronic Bronchitis

Phenotypes, Etiotypes, and Endotypes of Exacerbations of COPD

RESPrimaria 1ª Edición: 8 de Mayo de 2024 en formato híbrido

TRIPLE THERAPY AND CLINICAL CONTROL IN B+ COPD PATIENTS: A PRAGMATIC, PROSPECTIVE, RANDOMIZED TRIAL

Coffee Talk: CADSET-explaining the lung function tracker tool

Lung Tissue Multi-Layer Network Analysis Uncovers the Molecular Heterogeneity of COPD

COPD: systemic proteomic profiles in frequent and infrequent exacerbators

Peripheral Immune Cell Profiling Reveals Distinct Immune Hallmarks in Progressive Pulmonary Fibrosis

Pulmonary vascular reactivity in growth restricted fetuses using computational modelling and machine learning analysis of fetal Doppler waveforms

Cátedra UB de Salud Respiratoria

Recibe avisos de nuevas publicaciones

Legal

2024 © Cátedra UB de Salud Respiratoria. All rights reserved.

Entérate de
Nuestras Publicaciones

Noticias

Cátedra UB de Salud Respiratoria

Recibe avisos de nuevas publicaciones

Legal

2024 © Cátedra UB de Salud Respiratoria. All rights reserved.

Entérate de Nuestras Publicaciones

Entérate de
Nuestras Publicaciones